Paper Details

  1. Home
  2. Paper Details

Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial.

Author: HashimotoYoichiro, HirataKoichi, KomoriMika, OzekiAkichika, TanjiYuka

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Lasmiditan, a new oral acute migraine treatment without cardiovascular contraindications, is well-tolerated and effective for Japanese patients with migraine and cardiovascular risk factors (CVRFs). A phase 2 study found no relationship between the number of CVRFs and the incidence of treatment-emergent adverse events, and lasmiditan was effective in relieving pain, symptoms, and disability regardless of the number of CVRFs.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Some migraine treatments are contraindicated for patients with cardiovascular disease (CVD) or risk factors (CVRFs). We report safety and efficacy of lasmiditan, a new oral acute migraine treatment with no cardiovascular contraindication, in Japanese patients with CVRFs. RESEARCH DESIGN...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/14740338.2022.2078302

データ提供：米国国立医学図書館（NLM）

Lasmiditan for Migraine: A Safe and Effective Oasis in the Desert of Pain

Migraines are like a raging desert sandstorm, leaving sufferers in pain and discomfort. This research explores the potential of a new medication, lasmiditan, as a safe and effective treatment for migraine attacks, even in patients with cardiovascular risk factors. The study aims to investigate the safety and efficacy of lasmiditan in Japanese patients with migraine who also have cardiovascular risk factors. The researchers found that lasmiditan was well tolerated and effective in relieving pain, symptoms, and disability in patients with migraine and cardiovascular risk factors. This study offers hope for patients with migraine who may have been hesitant to try other medications due to their cardiovascular risk factors.

Lasmiditan: A Safe Haven in the Desert of Migraine

This study demonstrates the safety and efficacy of lasmiditan in treating migraine attacks, even in patients with cardiovascular risk factors, offering a potential solution for those who have been hesitant to explore other migraine treatments.

Finding Relief in the Desert of Pain: A New Approach to Migraine Treatment

The findings suggest that lasmiditan could offer a safe and effective haven for patients suffering from migraine, even those with cardiovascular risk factors. This research represents a significant step forward in the fight against migraine, offering a path to relief in the desert of pain.

Dr.Camel's Conclusion

Navigating the desert of migraine can be a difficult journey, filled with pain and discomfort. This study offers a glimmer of hope with lasmiditan, like a safe and effective oasis, that provides relief for patients with migraine, even those with cardiovascular risk factors. This research could pave the way for a more comfortable journey through the desert of migraine, offering a brighter future for those who suffer from this debilitating condition.

Date :
  1. Date Completed 2023-01-05
  2. Date Revised 2023-01-11
Further Info :

Pubmed ID

35748397

DOI: Digital Object Identifier

10.1080/14740338.2022.2078302

Related Literature

Article Analysis
・Effects of lasmiditan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.